Our strategy is to become a global cell & gene therapy company specialized to the research and development. We are advancing research programs against viral carrier-based gene therapy which is focusing on the treatment for neurological disorders and cancer. Our representative pipelines include KLS-2031 (on Phase 1/2a clinical trial in the U.S.) which is the treatment for neuropathic pain, and KLS-3021 (on preclinical study) which is the oncolytic viral therapy.
In our pursuit of distinctiveness in the development of gene therapy, we aims to progress our technology for viral carrier platform.
In addition, we will enhance our portfolio and reinforce our capability for biologics by introducing promising technologies and innovative ideas through open innovation. We aim to grow as a global forefront company through the development and successful commercialization of the next generation medicines, and to contribute to the improvement of human health and quality of life.